Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
or

Cynapsus Therapeutic (CYNAF)

Cynapsus Therapeutic (CYNAF)
0.9600 -0.0330 (-3.32%) 05/09/16 [OTC US]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime - - (-) -
Quote Overview for Mon, May 9th, 2016
Day Low
0.9600
Day High
0.9984
Open 0.9984
Previous Close 0.9930 0.9930
Volume 31,200 31,200
Avg Vol N/A N/A
Stochastic %K N/A N/A
Weighted Alpha N/A N/A
5-Day Change N/A (-3.32%) N/A (-3.32%)
52-Week Range 0.9494 - 1.0872 0.9494 - 1.0872
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure

Fundamentals

See More
  • Market Capitalization, $K 107,680
  • Shares Outstanding, K 110,310
  • Annual Sales, $ 0 K
  • Annual Income, $ 9,800 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.71
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.47
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.17
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/06/15
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/15
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.04
  • Growth Rate Est. (year over year) +2,497,600.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9494 +1.12%
on 04/18/16
Period Open: 1.0570
1.0872 -11.70%
on 04/18/16
-0.0970 (-9.18%)
since 02/24/14

Business Summary

Cynapsus Therapeutics, Inc. is a specialty pharmaceutical company engaged in developing a drug used to treat the symptoms of Parkinson's disease. The Company's drug candidate, APL-130277, is a reformulation of apomorphine, which is approved in an injection formulation to rescue patients from `off` episodes....

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 1.0112
1st Resistance Point 0.9856
Last Price 0.9600
1st Support Level 0.9472
2nd Support Level 0.9344
3rd Support Level N/A

See More

52-Week High 1.0872
Fibonacci 61.8% 1.0346
Fibonacci 50% 1.0183
Fibonacci 38.2% 1.0020
Last Price 0.9600
52-Week Low 0.9494

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar